| Symbol | LTPLF |
|---|---|
| Name | LTR PHARMA LTD. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | 4000 Australia QL 9/204 Alice Street |
| Telephone | +61 18 0051 9711 |
| Fax | — |
| — | |
| Website | https://ltrpharma.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. Additional info from OTC: |
No news found.